Try our Advanced Search for more refined results

IN RE: GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION

Track this case

Case overview

Case Number:

2:16-md-02724

Court:

Pennsylvania Eastern

Nature of Suit:

Other Statutes: Anti-Trust

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

CYNTHIA M. RUFE

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 05, 2021

    2 Sun Pharma US Units To Pay $85M In Generic Drugs MDL

    Two U.S. subsidiaries of Indian drugmaker Sun Pharma have agreed to shell out a combined $85 million to a proposed class of direct purchaser plaintiffs in sweeping multidistrict litigation over alleged price-fixing of generic drugs, the companies have reportedly disclosed.

  2. June 10, 2021

    Judge Slams Calif. For Discovery Violation In Generics MDL

    A Pennsylvania federal judge overseeing a sweeping multidistrict litigation program over alleged price-fixing of generic drugs expressed frustration during a hearing Thursday as she contemplated sanctioning the California Attorney General's Office over its failure to hand over data it may rely on in building its case.

  3. May 14, 2021

    AGs Say High Court Ruling Doesn't Weaken Drug Price Claims

    State attorneys general on Friday blasted a bid by generic-drug makers to use a recent U.S. Supreme Court ruling as a shield against the prosecutors' price-fixing claims, telling a Pennsylvania federal court that the justices' decision doesn't address the relevant law.

  4. May 07, 2021

    Dermatology Case Tapped As Bellwether In Generic Drug MDL

    A Pennsylvania federal judge has selected a case from state enforcers over dermatology treatments to serve as a bellwether in the multidistrict litigation over price-fixing in the generic-drug industry.

  5. May 05, 2021

    Generic-Drug Makers Knock States' Objection To Sanctions

    Generic-drug makers accused of participating in an industrywide price-fixing scheme are urging a Pennsylvania federal court to disregard state enforcers' objections to a special master's recommendation to sanction the California attorney general's office for failing to fulfill discovery obligations in the multidistrict litigation.

  6. April 27, 2021

    AGs Warn Against Sanctioning Calif. In Generics Pricing MDL

    The attorneys general of Pennsylvania, Oregon and Minnesota urged a Pennsylvania federal judge to reject a special master's recommendation to sanction the California Attorney General's Office for failing to fulfill discovery obligations in multidistrict litigation over inflated medication prices, arguing that it has broad implications.

  7. April 07, 2021

    States Too Late To Question Report In MDL, Drugmakers Say

    A coalition of generic-drug companies filed an opposition brief on Wednesday blasting a group of state attorneys general for contesting a special master's recommendation in sprawling multidistrict litigation accusing much of the generic-drug industry of price-fixing, arguing that the states' motion is untimely.

  8. April 06, 2021

    Calif. AG Says Sanctions Rec. 'Misunderstands' Generics MDL

    The California Attorney General's Office said a special master went too far in recommending sanctions against it for not living up to discovery obligations in a multidistrict litigation that accuses much of the generic-drug industry of price-fixing, saying Monday all the material is coming from the defendant drugmakers and third parties.

  9. March 30, 2021

    Generics Cos. Argue For Heritage Bellwether In Antitrust MDL

    A group of generic-drug makers facing multiple antitrust complaints for allegedly working in concert to inflate medication prices has urged a Pennsylvania federal judge to choose a case against Heritage Pharmaceuticals as the bellwether.

  10. March 23, 2021

    Generics MDL Special Master Says Calif. AG Merits Sanctions

    A special master on Monday recommended that the California Attorney General's Office be sanctioned for failing to live up to discovery promises in the sprawling multidistrict litigation that accuses much of the generic drug industry of price-fixing, saying the office should be limited to only evidence that was produced on deadline.